|
|
|
| home > white papers > How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction - Temptime Corporation |
|
|
 WHITE PAPERS |
|
Temptime Corporation
|
|
How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction
|
|
The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Kallik’s Release 6 sets new benchmarks for speed, accuracy and efficiency
Tamworth, UK – 15 June 2019 – Global provider of labelling and artwork management solutions, Kallik, is launching an update to its AMS360 solution – its Release 6, transforming the experience of the business user, whilst defining new benchmarks for speed, accuracy, and efficiency of global labelling and artwork processes.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Russia Orange Paper: 2nd Quarter 2014
Synergy Research Group
The Ministry of Health of Russian Federation approved 194 new clinical
trials of all types including local and bioequivalence studies during
the 2nd Quarter of 2014 (3% less than at the same period of the last
year).
The main contribution to the total number of studies was
made by multinational multi-center clinical trials (MMCT) and the number
of these studies stayed the same as in Q2 2013 – 81 studies. The number
of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to
59 in Q2 2014, a 22% decrease from last year’s figure. The number of
local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical
trials in Q2 2014.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
|
